vs
Side-by-side financial comparison of Claritev Corp (CTEV) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $246.6M, roughly 1.1× Claritev Corp). Claritev Corp runs the higher net margin — -32.7% vs -45.7%, a 13.0% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 6.2%). Claritev Corp produced more free cash flow last quarter ($36.4M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 2.5%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
CTEV vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $246.6M | $281.3M |
| Net Profit | $-80.6M | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | -3.1% | -43.0% |
| Net Margin | -32.7% | -45.7% |
| Revenue YoY | 6.2% | 39.4% |
| Net Profit YoY | 41.6% | -15.8% |
| EPS (diluted) | $-4.88 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $246.6M | $281.3M | ||
| Q3 25 | $246.0M | $265.2M | ||
| Q2 25 | $241.6M | $232.1M | ||
| Q1 25 | $231.3M | $203.5M | ||
| Q4 24 | $232.1M | $201.8M | ||
| Q3 24 | $230.5M | $191.5M | ||
| Q2 24 | $233.5M | $177.2M | ||
| Q1 24 | $234.5M | $168.5M |
| Q4 25 | $-80.6M | $-128.5M | ||
| Q3 25 | $-69.8M | $-92.7M | ||
| Q2 25 | $-62.6M | $-99.9M | ||
| Q1 25 | $-71.3M | $-95.2M | ||
| Q4 24 | $-138.0M | $-111.0M | ||
| Q3 24 | $-391.4M | $-107.8M | ||
| Q2 24 | $-576.7M | $-102.6M | ||
| Q1 24 | $-539.7M | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
| Q4 25 | -3.1% | -43.0% | ||
| Q3 25 | 4.1% | -37.3% | ||
| Q2 25 | 6.9% | -45.9% | ||
| Q1 25 | 4.2% | -54.6% | ||
| Q4 24 | -17.8% | -62.4% | ||
| Q3 24 | -146.7% | -61.3% | ||
| Q2 24 | -224.4% | -56.8% | ||
| Q1 24 | -207.4% | -59.2% |
| Q4 25 | -32.7% | -45.7% | ||
| Q3 25 | -28.4% | -35.0% | ||
| Q2 25 | -25.9% | -43.0% | ||
| Q1 25 | -30.8% | -46.8% | ||
| Q4 24 | -59.4% | -55.0% | ||
| Q3 24 | -169.8% | -56.3% | ||
| Q2 24 | -247.0% | -57.9% | ||
| Q1 24 | -230.1% | -68.2% |
| Q4 25 | $-4.88 | $-1.01 | ||
| Q3 25 | $-4.23 | $-0.74 | ||
| Q2 25 | $-3.81 | $-0.80 | ||
| Q1 25 | $-4.38 | $-0.77 | ||
| Q4 24 | $-8.49 | $-0.90 | ||
| Q3 24 | $-24.25 | $-0.88 | ||
| Q2 24 | $-35.78 | $-0.84 | ||
| Q1 24 | $-33.40 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.8M | $378.2M |
| Total DebtLower is stronger | $4.6B | $1.5B |
| Stockholders' EquityBook value | $-173.9M | $-99.3M |
| Total Assets | $4.9B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.8M | $378.2M | ||
| Q3 25 | $39.2M | $580.0M | ||
| Q2 25 | $56.4M | $629.1M | ||
| Q1 25 | $23.1M | $698.6M | ||
| Q4 24 | $16.8M | $525.5M | ||
| Q3 24 | $86.6M | $585.0M | ||
| Q2 24 | $48.8M | $933.7M | ||
| Q1 24 | $58.7M | $1.0B |
| Q4 25 | $4.6B | $1.5B | ||
| Q3 25 | $4.5B | $1.1B | ||
| Q2 25 | $4.5B | $1.1B | ||
| Q1 25 | $4.5B | $1.1B | ||
| Q4 24 | $4.5B | $1.1B | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $4.5B | — | ||
| Q1 24 | $4.5B | — |
| Q4 25 | $-173.9M | $-99.3M | ||
| Q3 25 | $-101.8M | $-354.5M | ||
| Q2 25 | $-39.9M | $-305.5M | ||
| Q1 25 | $14.8M | $-250.8M | ||
| Q4 24 | $84.0M | $-139.6M | ||
| Q3 24 | $207.6M | $-60.1M | ||
| Q2 24 | $603.4M | $-1.6M | ||
| Q1 24 | $1.2B | $68.3M |
| Q4 25 | $4.9B | $2.0B | ||
| Q3 25 | $5.0B | $1.3B | ||
| Q2 25 | $5.1B | $1.3B | ||
| Q1 25 | $5.1B | $1.3B | ||
| Q4 24 | $5.2B | $1.5B | ||
| Q3 24 | $5.3B | $1.5B | ||
| Q2 24 | $5.7B | $1.6B | ||
| Q1 24 | $6.4B | $1.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 304.87× | — | ||
| Q4 24 | 53.67× | — | ||
| Q3 24 | 21.73× | — | ||
| Q2 24 | 7.48× | — | ||
| Q1 24 | 3.85× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $66.3M | $-26.4M |
| Free Cash FlowOCF − Capex | $36.4M | $-54.2M |
| FCF MarginFCF / Revenue | 14.8% | -19.3% |
| Capex IntensityCapex / Revenue | 12.1% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.3M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.3M | $-26.4M | ||
| Q3 25 | $19.9M | $-35.4M | ||
| Q2 25 | $61.2M | $-60.3M | ||
| Q1 25 | $-30.1M | $-62.7M | ||
| Q4 24 | $-33.4M | $-64.5M | ||
| Q3 24 | $72.8M | $-51.1M | ||
| Q2 24 | $18.5M | $-94.0M | ||
| Q1 24 | $49.7M | $-30.3M |
| Q4 25 | $36.4M | $-54.2M | ||
| Q3 25 | $-16.3M | $-45.8M | ||
| Q2 25 | $36.6M | $-65.9M | ||
| Q1 25 | $-68.9M | $-67.1M | ||
| Q4 24 | $-63.8M | $-83.4M | ||
| Q3 24 | $41.1M | $-55.3M | ||
| Q2 24 | $-7.0M | $-99.1M | ||
| Q1 24 | $19.2M | $-37.2M |
| Q4 25 | 14.8% | -19.3% | ||
| Q3 25 | -6.6% | -17.3% | ||
| Q2 25 | 15.2% | -28.4% | ||
| Q1 25 | -29.8% | -33.0% | ||
| Q4 24 | -27.5% | -41.3% | ||
| Q3 24 | 17.8% | -28.9% | ||
| Q2 24 | -3.0% | -55.9% | ||
| Q1 24 | 8.2% | -22.1% |
| Q4 25 | 12.1% | 9.9% | ||
| Q3 25 | 14.7% | 3.9% | ||
| Q2 25 | 10.2% | 2.4% | ||
| Q1 25 | 16.8% | 2.2% | ||
| Q4 24 | 13.1% | 9.4% | ||
| Q3 24 | 13.8% | 2.2% | ||
| Q2 24 | 10.9% | 2.9% | ||
| Q1 24 | 13.0% | 4.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTEV
Segment breakdown not available.
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
